DAPK3 and renal carcinoma: Therefore, we not only revealed a novel RBPJ/DAPK3/UBE3A/PBRM1/p21 axis but also identified a combination strategy for overcoming the resistance of renal cancer cells to CDK4/6 inhibitors.